Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Medicenna Therapeutics Corp. (MDNAF) had Consolidated Net Income/Loss of $-13.32M for the most recently reported fiscal year, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-13.32M |
|
-- |
|
-- |
|
$16.23M |
|
$-16.23M |
|
$2.90M |
|
$-13.32M |
|
$-13.32M |
|
$-13.32M |
|
$-13.32M |
|
|
Consolidated Net Income/Loss |
$-13.32M |
$-13.32M |
|
$-16.23M |
|
$-16.17M |
|
83.19M |
|
83.19M |
|
$-0.16 |
|
$-0.16 |
|
| Balance Sheet Financials | |
$6.02M |
|
$0.00M |
|
$0.10M |
|
$6.12M |
|
$3.96M |
|
-- |
|
$0.37M |
|
$4.32M |
|
$1.80M |
|
$1.76M |
|
$1.80M |
|
83.42M |
|
| Cash Flow Statement Financials | |
$-12.97M |
|
$0.00M |
|
$-0.01M |
|
$17.98M |
|
$4.52M |
|
$-13.45M |
|
$1.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.52 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.97M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-741.70% |
|
-756.02% |
|
-217.75% |
|
-741.70% |
|
$0.02 |
|
$-0.16 |
|
$-0.16 |
|